(NASDAQ: JANX) Janux Therapeutics's forecast annual revenue growth rate of 157.94% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.36%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.64%.
Janux Therapeutics's revenue in 2024 is $7,287,000.On average, 3 Wall Street analysts forecast JANX's revenue for 2024 to be $109,197,505, with the lowest JANX revenue forecast at $64,813,334, and the highest JANX revenue forecast at $174,736,748. On average, 2 Wall Street analysts forecast JANX's revenue for 2027 to be $871,350,459, with the lowest JANX revenue forecast at $668,355,098, and the highest JANX revenue forecast at $1,074,345,820.
In 2028, JANX is forecast to generate $7,176,961,923 in revenue, with the lowest revenue forecast at $6,156,748,200 and the highest revenue forecast at $7,865,227,677.